Arbutus Biopharma Corporation
ABUS
$3.29
-$0.05-1.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.53M | -19.72M | -19.80M | -17.88M | -19.31M |
| Total Depreciation and Amortization | 333.00K | 336.00K | 356.00K | 355.00K | 359.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.11M | 1.14M | 2.18M | 1.08M | 174.00K |
| Change in Net Operating Assets | -229.00K | -2.50M | 2.76M | -2.86M | 1.49M |
| Cash from Operations | -10.32M | -20.74M | -14.50M | -19.30M | -17.29M |
| Capital Expenditure | -86.00K | 0.00 | -1.00K | -95.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.50M | -11.99M | 9.83M | 11.79M | 22.23M |
| Cash from Investing | 13.41M | -11.99M | 9.83M | 11.69M | 22.23M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.42M | 1.78M | 24.37M | 24.43M | 3.81M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.42M | 1.78M | 24.37M | 24.43M | 3.81M |
| Foreign Exchange rate Adjustments | -33.00K | 5.00K | -8.00K | -13.00K | 14.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.48M | -30.94M | 19.69M | 16.82M | 8.75M |